Literature DB >> 17241671

Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS.

Sylva Janovská1, Ivona Pávková, Martin Hubálek, Juraj Lenco, Ales Macela, Jirí Stulík.   

Abstract

Francisella tularensis is a Gram-negative, facultative intracellular bacterium causing disease in many mammalian species. The low infectious dose of F. tularensis and the ease of air-borne transmission are the main features responsible for the classification of this bacterium as a potential biological weapon. The live attenuated strain of F. tularensis live vaccine strain (LVS) is currently only effective vaccine against tularemia, however, this type of vaccine has not been approved for human use. In the presented study, sub-immunoproteome analysis was performed to search for new immunogenic proteins of Francisella tularensis LVS grown under different conditions. By this approach 35 immunoreactive antigens were identified, 19 of them showed to be novel immunogens. In conclusion, sub-immunoproteome analysis resulted in successful identification of novel immunoreactive proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17241671     DOI: 10.1016/j.imlet.2006.12.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  25 in total

1.  Multimethodological approach to identification of glycoproteins from the proteome of Francisella tularensis, an intracellular microorganism.

Authors:  Lucie Balonova; Lenka Hernychova; Benjamin F Mann; Marek Link; Zuzana Bilkova; Milos V Novotny; Jiri Stulik
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 4.  The sweet tooth of bacteria: common themes in bacterial glycoconjugates.

Authors:  Hanne L P Tytgat; Sarah Lebeer
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

5.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

6.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

7.  Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Authors:  Qingmei Jia; Richard Bowen; Bai-Yu Lee; Barbara Jane Dillon; Saša Masleša-Galić; Marcus A Horwitz
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

8.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

9.  Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV).

Authors:  Yong-Zhang Zhu; Cheng-Song Cai; Wei Zhang; Hong-Xiong Guo; Jin-Ping Zhang; Ya-Yong Ji; Guang-Yuan Ma; Jia-Lin Wu; Qing-Tian Li; Cheng-Ping Lu; Xiao-Kui Guo
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

Review 10.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.